This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sinclair, D. B. Articles by Breault, R. Search for Related Content PubMed PubMed Citation Articles by Sinclair, D. B. Articles by Breault, R. Social Bookmarking                         What's this?

Valproic Acid—Induced Pancreatitis in Childhood Epilepsy: Case Series and Review

Division of Pediatric Neurology University of Alberta, Edmonton, AB, Canada, bsinclai{at}cha.ab.ca

Marjorie Berg, MSN

Division of Pediatric Neurology University of Alberta, Edmonton, AB, Canada

Rene Breault, BSc

Division of Pediatric Neurology University of Alberta, Edmonton, AB, Canada

In the past 6 years, 11 children on valproic acid have developed pancreatitis in our children's hospital. Valproic acid has been used as one of the primary anticonvulsants for generalized seizures in children for the past 25 years. A literature review reveals mostly singular reports of pancreatitis over the past decade. The charts of the 11 patients with valproic acid—induced pancreatitis were reviewed. Dosage, valproic acid serum levels, duration of therapy, and concomitant medications were examined. Families were contacted by telephone to determine the formulation (brand name vs generic) of valproic acid at the time of diagnosis. Six girls and five boys were studied. The ages ranged from 4 to 16 years. Eight of 11 children presented with an acute abdomen. Unexpectedly, three children presented with a flulike illness. Serum lipase values ranged from 341 to 5576 U/L (normal range < 190 U/L). The dose of valproic acid ranged from 20 to 50 mg/kg. Serum levels ranged from 334 to 884 µmol/L (therapeutic range 350—800 µmol/L). Six of the patients were on monotherapy. Seven children were on brand-name drugs. Four of the children had an abnormal neurologic syndromic diagnosis (West syndrome, Rett syndrome, Lowe syndrome, and Angelman's syndrome). Six of the children had a history of drug allergies with a skin rash. Valproic acid was reintroduced in one child and resulted in a second episode of pancreatitis. Resolution of symptoms usually took several weeks following discontinuation of the drug. No association was found with valproic acid dosage, type of preparation, serum levels, duration of therapy, or presence of concomitant medications. Pancreatitis is a severe adverse effect of valproic acid use in children. Dose, duration of treatment, serum valproic acid levels, generic preparation, and the presence of concomitant antiepileptic drugs do not appear to be risk factors. Children with known drug sensitivity might be at risk. Lipase levels at the time of an acute abdomen or a flulike illness in epileptic children taking valproic acid can reveal early stages of pancreatitis and are recommended. (J Child Neurol 2004;19:498—502).

Journal of Child Neurology, Vol. 19, No. 7, 498-502 (2004)
DOI: 10.1177/08830738040190070401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Glauser, G. Kluger, R. Sachdeo, G. Krauss, C. Perdomo, and S. Arroyo Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome Neurology, May 20, 2008; 70(21): 1950 - 1958. [Abstract] [Full Text] [PDF]

				S. L. Werlin and D. L. Fish The Spectrum of Valproic Acid-Associated Pancreatitis Pediatrics, October 1, 2006; 118(4): 1660 - 1663. [Abstract] [Full Text] [PDF]